Surveys South Korean adults with bladder-lining cancer receiving PADCEV Injection
Collects records of adults with urothelial cancer treated with enfortumab vedotin.
Key facts
- Who runs it
- Astellas Pharma Korea, Inc.
- Where
- Busan, Daegu, Daejeon, Goyang-si, Incheon, Jeollanam-do, Jeonju, Seoul, and Suwon, South KoreaSee the 18 sites
- Trial code
- Registry title
- A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
- Status
- Recruiting
- People taking part
- 228 people, planned
- Started
- 1 Nov 2023
- Expected to end
- 31 Jul 2027
- Type of study
- Observational
- Treatments tested
- Enfortumab Vedotin
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in South Korea with locally advanced or metastatic urothelial cancer who are treated with PADCEV Injection. It only collects information on their care.
- Age
- Adults
- Sex
- All sexes can join.
- Disease stage
- Locally advanced or metastatic urothelial cancer (cancer of the bladder lining).
- Earlier treatment
- People must be receiving PADCEV Injection (enfortumab vedotin) according to the approved local label.
Main reasons for not taking part
- Any reason why PADCEV Injection must not be used, according to the approved local label
- Receiving or going to receive any investigational medicine during the observation period
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients who receive treatment with PADCEV Injection, according to the approved local label
Who cannot take part
- Patients with any contraindication for PADCEV Injection, according to the approved local label
- Patients who receive or are going to receive any investigational medicine during the observation period
Where in South Korea
- BusanHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- BusanHospital not named in the registryContact: Astellas Pharma Global Development, Inc.No longer taking part
- BusanHospital not named in the registryContact: Astellas Pharma Global Development, Inc.No longer taking part
- BusanHospital not named in the registryContact: Astellas Pharma Global Development, Inc.No longer taking part
- DaeguHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- DaejeonHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Goyang-si, Gyeonggi-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- IncheonHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Jeollanam-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Jeonju, Jeonbuk-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- SeoulHospital not named in the registryContact: Astellas Pharma Global Development, Inc.No longer taking part
- Suwon, Gyeonggi-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
- Suwon, Gyeonggi-doHospital not named in the registryContact: Astellas Pharma Global Development, Inc.Taking people
About the trial
What the trial wants to find out
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.
Read full original descriptionShow less
People in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed PADCEV Injection and other medicines to treat their cancer. People in the study will be treated according to their clinic's standard practice. This study is about collecting information only.
This study will survey people who know they are receiving PADCEV Injection. The aims of the study are to check outcomes of treatment with PADCEV and record any medical problems during the study.
Once a doctor has prescribed PADCEV Injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. During this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. If a person in the study stops taking PADCEV Injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of PADCEV Injection or until they start a different medicine for their cancer.
The group in the trial
- PADCEV
Patients who receive PADCEV Injection 20 mg and 30 mg (enfortumab vedotin) in routine clinical practice according to the drug label approved at the time of marketing authorization.
Treatment: Enfortumab Vedotin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea
- Plain-language title
- Surveys South Korean adults with bladder-lining cancer receiving PADCEV InjectionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 October 2026